Marizyme, Inc.
MRZM · OTC
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.01 | 0.01 | 0.00 |
| FCF Yield | -14.92% | -12.51% | -6.79% | -27.64% |
| EV / EBITDA | -51.53 | -29.00 | -19.45 | -2.95 |
| Quality | ||||
| ROIC | -7.71% | -8.84% | -7.33% | -114.54% |
| Gross Margin | 0.00% | 0.00% | -566.36% | -77.35% |
| Cash Conversion Ratio | 0.22 | 0.18 | 0.14 | 0.13 |
| Growth | ||||
| Revenue 3-Year CAGR | 34.05% | 113.79% | 59.16% | 45.36% |
| Free Cash Flow Growth | -31.10% | 11.75% | 32.40% | -9.03% |
| Safety | ||||
| Net Debt / EBITDA | -41.30 | -22.42 | -12.70 | -2.37 |
| Interest Coverage | -1.23 | -0.46 | -0.33 | -2.90 |
| Efficiency | ||||
| Inventory Turnover | 7.84 | 8.28 | 14.39 | 10.74 |
| Cash Conversion Cycle | -1,428.08 | -1,311.12 | -957.88 | -681.21 |